To observe the therapeutic effect of Sanren decoction combined with budesonide formoterol inhalant and budesonide formoterol inhalant in the treatment of obese patients with asthma,then evaluate the efficacy of Sanren decoction combined with budesonide formoterol inhalant in obese patients with asthma.Methods:This was a prospective randomized control study in which 71 obese patients with asthma were randomly divided into observation group (n=33) and control group (n=38).Patients in the observation group were treated with Sanren decoction combined with budesonide formoterol inhalant,while patients in the control group were treated with budesonide formoterol inhalant.In the observation group,patients took one dose of Sanren per day,with 200 mL per time and twice orally.As for budesonide formoterol inhalant,it was inhaled twice a day,a suction once (160ug/4.5 μg) both in observation group and control group.After 4 weeks of treatment,questionnaires (asthma control questionnaire (ACQ) score,asthma control test (ACT) score) and pulmonary function tests were performed to assess overall control of asthma.Results:After 4 weeks of treatment,the scores of ACT and ACQ and pulmonary function in the observation group and the control group were significantly better than those before treatment (P<0.05).There was no significant difference between the observation group and the control group in FEV1% predicted (P=0.45) and PEF% predicted (P=0.45).However,the ACT score (P=0.00) and ACQ score (P=0.00) in observation group were better than those of the control group,and the overall control rate in observation group (93.9%) was better than that of the control group (86.8%) with significant statistical difference (χ2=7.89,P=0.019).Conclusion:The combination of Sanren decoction with budesonide formoterol inhalant has an advantage in improving asthma symptoms and overall control rate compared with using inhalants alone.